You can buy or sell Syros and other stocks, options, ETFs, and crypto commission-free!
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Read More The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 2
What Are Analysts Expecting From Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Over The Next Few Years?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) announced its latest earnings update in December 2018, which suggested that losses became smaller relative to the prior year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts predict Syros Pharmaceuticals's earnings growth outlook over the next couple of years and whether the futur...
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 14.04%. A quarter ago, it was expected that this company would post a loss of $0.49 per share when it actually produced a loss of $0.54, delivering a surprise of -10.20%. Over the last four quarters, the com...
-$0.57 per share
-$0.49 per share